1. Home
  2. LQDA vs KSS Comparison

LQDA vs KSS Comparison

Compare LQDA & KSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • KSS
  • Stock Information
  • Founded
  • LQDA 2004
  • KSS 1962
  • Country
  • LQDA United States
  • KSS United States
  • Employees
  • LQDA N/A
  • KSS N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • KSS Department/Specialty Retail Stores
  • Sector
  • LQDA Health Care
  • KSS Consumer Discretionary
  • Exchange
  • LQDA Nasdaq
  • KSS Nasdaq
  • Market Cap
  • LQDA 1.9B
  • KSS 1.9B
  • IPO Year
  • LQDA 2018
  • KSS 1992
  • Fundamental
  • Price
  • LQDA $24.53
  • KSS $15.88
  • Analyst Decision
  • LQDA Strong Buy
  • KSS Sell
  • Analyst Count
  • LQDA 9
  • KSS 14
  • Target Price
  • LQDA $32.67
  • KSS $11.88
  • AVG Volume (30 Days)
  • LQDA 2.2M
  • KSS 4.2M
  • Earning Date
  • LQDA 11-03-2025
  • KSS 11-25-2025
  • Dividend Yield
  • LQDA N/A
  • KSS 3.17%
  • EPS Growth
  • LQDA N/A
  • KSS N/A
  • EPS
  • LQDA N/A
  • KSS 1.86
  • Revenue
  • LQDA $19,322,000.00
  • KSS $15,886,000,000.00
  • Revenue This Year
  • LQDA $424.31
  • KSS N/A
  • Revenue Next Year
  • LQDA $359.32
  • KSS N/A
  • P/E Ratio
  • LQDA N/A
  • KSS $8.47
  • Revenue Growth
  • LQDA 30.20
  • KSS N/A
  • 52 Week Low
  • LQDA $9.71
  • KSS $6.04
  • 52 Week High
  • LQDA $29.94
  • KSS $21.39
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 52.65
  • KSS 48.20
  • Support Level
  • LQDA $22.05
  • KSS $15.50
  • Resistance Level
  • LQDA $24.34
  • KSS $17.15
  • Average True Range (ATR)
  • LQDA 1.26
  • KSS 0.69
  • MACD
  • LQDA 0.10
  • KSS -0.04
  • Stochastic Oscillator
  • LQDA 60.51
  • KSS 34.42

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About KSS Kohl's Corporation

Kohl's operates about 1,150 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also has a large digital sales operation. Women's apparel is Kohl's largest category, having generated 25% of its 2024 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.

Share on Social Networks: